IMS Health is an international company that supplies the pharmaceutical industry with sales data and consulting services. IMS Health was founded in 1954 by Bill Froch and David Dubow. Today IMS has operations in more than 100 countries, a global workforce of 7,600+ employees, and revenues of $2 billion. It recently moved its headquarters from Fairfield, CT to Norwalk, CT.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2012 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of IMS Health
Names of Lobbyists
Most Frequently Disclosed Lobbying Issues
- Health Issues
RegulationsMentioned in 48 dockets; Submitted to 3 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "IMS Health" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for IMS Health
- Toggle 1 HHS HIPAA Privacy Rule Accounting of Disclosures under the Health Information Technology for Economic and Clinical Health Act 2011
- Toggle 1 HHS Nationwide Health Information Network: Conditions for Trusted Exchange 2012
- Toggle 1 HHS Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators 2011
Mentions in Document Text
View all mentions data for IMS Health
- Toggle 13 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Healthcare Professional Survey of Prescription Drug Promotion 2012
- Toggle 5 HHS Nationwide Health Information Network: Conditions for Trusted Exchange 2012
- Toggle 5 FDA Draft Guidance for Industry on Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices; Availability 2011
- Toggle 5 HHS Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators 2011
- Toggle 4 FDA Take The Actions Described in the Peitition With Respect to Endo's Discontinued Opana® ER (OxymorphoneHCI) Extended-rekease Tablets 2012
- Toggle 3 FDA Communications and Activities Related to Off-Label Uses of Marketed Products and Use of Products Not Yet Legally Marketed; Request for Information and Comments 2011
- Toggle 2 ITA Request for Public Comments Concerning Regulatory Cooperation between the United States and the European Union that Would Help Eliminate or Reduce Unnecessary Divergences in Regulation and in Standards Used in Regulation that Impede U.S. Exports 2011
- Toggle 2 HHS Health Information Technology; HIT Policy Committee: Request for Comment Regarding the Stage 3 Definition of Meaningful Use of Electronic Health Records (EHRs) 2012
- Toggle 2 HHS HIPAA Privacy Rule Accounting of Disclosures under the Health Information Technology for Economic and Clinical Health Act 2011
- Toggle 2 FDA Request That the Food and Drug Adminstration Make a Determination That OxyContin (Oxycodone Hydrochloride Extended-Releases) Tablets, 10 mg, 15 mg, 20 mg, 40 mg, 60 mg, 80 mg and 160 mg Withdrawn From Sale for Reasons Other Than Safety or Effectiveness 2011